IQVIA Holdings (IQV) is a $16.3 billion-revenue healthcare intelligence and clinical research company headquartered in Durham, North Carolina. The company runs clinical trials for the world’s largest pharmaceutical companies, maintains 1.2 billion longitudinal patient records across 68 petabytes of proprietary data, and employs 93,000 people in over 100 countries. It generated $2.7 billion in operating cash flow in 2025, earned $1.36 billion in net income, and carries $15.8 billion in debt against $6.6 billion in total equity. Its contracted backlog stands at $34.2 billion.
The company exists because of a 2016 merger between Quintiles, the world’s largest CRO, and IMS Health, the dominant provider of prescription tracking data and healthcare analytics. That combination created something unusual: a company that both runs the clinical trials to get drugs approved and sells the commercial data and analytics that help pharmaceutical companies sell those drugs once they’re on the market. The central question for IQVIA is whether this integrated model, and the data moat underneath it, justifies a capital structure that requires the business to generate over $700 million a year just to service its interest payments.
The Merger That Built IQVIA
IQVIA did not grow organically into its current form. It was assembled.
Quintiles Transnational, founded in 1982 by Dennis Gillings at the University of North Carolina, grew into the world’s largest CRO. The business model was straightforward: pharmaceutical companies outsource the expensive, complex work of running clinical trials to Quintiles, which built the global infrastructure to recruit patients, manage trial sites, collect data, and navigate regulatory submissions across dozens of countries. By the time of the merger, Quintiles had roughly 50,000 employees focused on drug development.
IMS Health had even deeper roots. Founded in 1954, it became the definitive source of pharmaceutical prescription data in the United States and eventually worldwide. IMS tracked which drugs were being prescribed, by whom, and in what volumes, then sold that intelligence back to pharmaceutical companies for commercial planning, sales force deployment, and competitive benchmarking. Over six decades, IMS built relationships with 150,000 data suppliers and accumulated what would become the largest proprietary healthcare dataset in the world.
Both companies had been through leveraged buyouts and public offerings before the merger. TPG Capital, Leonard Green & Partners, and other private equity sponsors took Quintiles private in 2003, then brought it back to public markets in 2013. IMS Health went through a similar cycle with TPG and other sponsors. By 2016, both companies were publicly traded and looking for growth.
The merger closed in October 2016. Ari Bousbib, who had been CEO of IMS Health since 2010, became Chairman and CEO of the combined entity. The logic was that combining Quintiles’ clinical trial execution with IMS Health’s data assets would create what management calls “Connected Intelligence,” a feedback loop where data from commercial operations informs clinical trial design, and clinical trial data feeds back into commercial analytics.
The name “IQVIA” was adopted in November 2017. The “I” and “Q” reference the two predecessor companies. The “VIA” was described as representing the path forward. Whatever you think of the branding exercise, the underlying business combination was substantive.
What IQVIA Does
IQVIA operates through three reportable segments, though this is changing. Effective January 1, 2026, the company is reorganizing into two segments: Commercial Solutions and R&D Solutions. The 2025 financials still reflect the three-segment structure.
Technology & Analytics Solutions
This segment generated $6.6 billion in revenue in 2025, up 7.6% year over year, and earned $1.6 billion in segment profit at a 24.3% margin. It employs roughly 31,000 people.
The core of this business is IQVIA’s proprietary healthcare data. The company processes 120 billion healthcare records per year from 150,000 data suppliers. It tracks prescription activity covering roughly 90% of global pharmaceutical sales by revenue. It maintains reference databases on 22 million healthcare professionals and 2 million healthcare organizations. This data is cleaned, linked, and de-identified, then sold to pharmaceutical companies as analytics products, consulting engagements, and SaaS platforms.
Key product lines include real-world evidence generation (using claims, EMR, and registry data to demonstrate drug effectiveness outside of clinical trials), commercial analytics (measuring sales force effectiveness, market share, and prescribing trends), and technology platforms like the Orchestrated Customer Engagement suite. The company also offers consulting services, though it does not break out consulting revenue separately.
Research & Development Solutions
This is the largest segment at $8.9 billion in revenue, up 4.3% year over year, with $1.9 billion in segment profit at a 21.9% margin. It employs roughly 51,000 people.
This is the CRO business inherited from Quintiles. IQVIA manages clinical trials from early-phase (first-in-human studies) through large-scale Phase III registrational trials and post-approval Phase IV studies. The company handles everything from protocol design and site selection to patient recruitment, data collection, biostatistics, regulatory submissions, and pharmacovigilance.
The contracted backlog for this segment was $32.7 billion at year-end 2025, up 5.3% from 2024. New business wins in 2025 totaled $10.7 billion, representing a book-to-bill ratio above 1.0x and indicating continued demand growth. Backlog is a critical metric for CRO businesses because it represents contracted future revenue, though contracts can typically be cancelled with 30 to 90 days’ notice.
IQVIA also operates laboratory services through a joint venture with Quest Diagnostics, providing genomic analysis, biomarker testing, and central lab services for clinical trials.
Contract Sales & Medical Solutions
The smallest segment at $788 million in revenue, up 9.7% year over year, with $48 million in segment profit at a 6.1% margin. It employs roughly 7,000 people.
This business deploys contract sales representatives on behalf of pharmaceutical companies. Rather than hiring, training, and managing their own sales forces, pharma companies can outsource that function to IQVIA. The segment also provides medical affairs services, real-world evidence generation at the point of care, and patient engagement programs.
The low margin reflects the labor-intensive, people-deployment nature of this business. It is the least differentiated of the three segments and is being folded into the broader Commercial Solutions segment in 2026.
The Data Moat
IQVIA’s most defensible asset is not its clinical trial infrastructure or its consulting practice. It is the data.
The company maintains 68 petabytes of proprietary healthcare data, built over seven decades through IMS Health’s original relationships with pharmacies, hospitals, payers, and electronic medical record systems. The dataset includes 1.2 billion unique longitudinal patient records, meaning the company can track individual (de-identified) patients across prescriptions, diagnoses, procedures, and outcomes over time. It processes 120 billion healthcare records annually from 150,000 data suppliers across more than 100 countries.
This data cannot be replicated quickly. The relationships with data suppliers took decades to establish. The cleaning, linking, and de-identification infrastructure is purpose-built for healthcare’s regulatory environment. A competitor starting from scratch would need to negotiate thousands of data-sharing agreements, build compliant data pipelines across dozens of regulatory jurisdictions, and accumulate years of longitudinal history before the dataset becomes analytically useful.
The data feeds both sides of the business. On the commercial side, pharmaceutical companies use IQVIA’s prescription tracking and market intelligence to measure sales force effectiveness, size markets, and track competitive dynamics. On the R&D side, the same data helps design clinical trials by identifying patient populations, selecting trial sites based on prescribing patterns, and generating real-world evidence for regulatory submissions. Management’s thesis is that this cross-pollination between commercial data and clinical operations creates value that neither business could deliver independently.
Whether the moat is as wide as it appears depends on how you assess the AI risk. IQVIA filed over 90 AI patent applications in 2025 and has deployed more than 150 specialized AI agents across its workflows. But the 10-K risk factors acknowledge the other side of that coin: advances in AI and large language models could allow pharmaceutical companies to perform analytics and clinical development tasks internally that they currently outsource to IQVIA. If open-source AI tools reduce the cost of analyzing large healthcare datasets, the premium IQVIA charges for its proprietary data and analytics could compress.
The Veeva Problem
IQVIA’s competitive landscape includes dozens of CROs, consulting firms, and data companies. But the most strategically interesting rivalry is with Veeva Systems.
Veeva built its business selling cloud software to the same life sciences customers IQVIA serves. Veeva’s Commercial Cloud provides CRM, marketing, and content management tools for pharmaceutical sales teams. Its R&D Cloud handles clinical trial management, regulatory submissions, quality systems, and safety reporting. And its Data Cloud competes directly with IQVIA’s commercial data products, offering prescription data, claims data, and patient-level analytics.
The competitive tension escalated in 2022 when Veeva announced it was rebuilding its CRM product on its proprietary Vault platform, migrating away from the Salesforce Force.com infrastructure it had used since the company’s founding. That migration involves moving roughly 627 customers off Salesforce by December 2029.
Salesforce’s response was to partner with IQVIA. In April 2024, IQVIA licensed its life sciences CRM software to Salesforce, giving Salesforce a competing product to offer pharmaceutical companies as they evaluate whether to follow Veeva to Vault CRM or switch vendors entirely. Veeva’s 10-K confirms the competitive impact: the company discloses that certain large Veeva CRM customers have committed to purchasing Salesforce’s CRM solutions, and that a number of customers have informed Veeva of their intent to move.
For IQVIA, the Salesforce partnership is an offensive play into Veeva’s territory. CRM licensing fees are unlikely to be material to a $16.3 billion revenue base today, and neither company discloses specific financial metrics for the partnership. But the strategic value is in cross-selling. If IQVIA can establish CRM relationships with pharmaceutical sales teams through the Salesforce channel, it creates a new entry point for its data and analytics products, which is where the real margin sits.
The risk is execution. IQVIA is a data and services company, not a software company. Building and maintaining enterprise SaaS products requires a different organizational muscle than running clinical trials or selling data subscriptions. Veeva has spent 17 years building life sciences software and has 1,552 customers embedded on its platform. Displacing an incumbent in enterprise software, particularly one whose applications share a unified data layer, is difficult even with a strong channel partner.
The two companies also settled all outstanding litigation in August 2025, dismissing claims that had been running since 2017. That cleared the legal overhang and allows both companies to compete on product rather than in courtrooms.
Financial Profile
IQVIA’s income statement tells the story of a high-revenue, moderate-margin business with a significant debt overhang.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $16.31B | $15.41B | $14.98B |
| Cost of Revenue | $10.61B | $10.06B | $9.86B |
| Gross Profit | $5.70B | $5.35B | $5.12B |
| Gross Margin | 34.9% | 34.7% | 34.2% |
| SG&A | $2.50B | $2.40B | $2.35B |
| Operating Income | $2.18B | $1.96B | $1.81B |
| Operating Margin | 13.4% | 12.7% | 12.1% |
| Net Income | $1.36B | $1.09B | $1.05B |
| Diluted EPS | $7.77 | $5.98 | $5.64 |
Revenue grew 5.9% in 2025, consistent with the company’s stated algorithm of 6-9% annual top-line growth driven by biopharma spending increases, outsourcing trends, share gains, and acquisitions. Gross margins have been stable in the 34-35% range. Operating margins have expanded modestly each year as the company extracts efficiency from the merged organization.
The adjusted numbers management prefers tell a more generous story. Adjusted EBITDA was $3.8 billion in 2025 (23.1% margin), and adjusted diluted EPS was $11.92, up 7.1% year over year. The gap between GAAP net income ($1.36B) and adjusted figures reflects $636 million in amortization of acquisition-related intangibles, $203 million in stock-based compensation, $167 million in restructuring charges, and various transaction and integration costs. These adjustments are not unusual for a company built through M&A, but the amortization alone is nearly half of GAAP net income, and it will persist for years given the $12.4 billion in goodwill and $4.5 billion in other intangible assets on the balance sheet.
Segment Economics
| Segment | Revenue | Profit | Margin |
|---|---|---|---|
| Technology & Analytics | $6.63B | $1.61B | 24.3% |
| R&D Solutions | $8.90B | $1.95B | 21.9% |
| Contract Sales & Medical | $788M | $48M | 6.1% |
Technology & Analytics earns the highest margins because data and analytics products carry significant operating leverage. Once the data infrastructure exists, incremental revenue from new clients or expanded usage drops through at high margins. R&D Solutions margins are lower but respectable for a labor-intensive CRO business. Contract Sales is essentially a staffing operation and earns accordingly.
The Debt Stack
The balance sheet is where the merger’s financial legacy is most visible.
| Item | Amount |
|---|---|
| Cash and equivalents | $1.98B |
| Total debt | $15.8B |
| Net debt | $13.8B |
| Stockholders’ equity | $6.6B |
| Goodwill | $12.4B |
| Other intangible assets | $4.5B |
Net leverage stood at 3.63x adjusted EBITDA at year-end 2025. Interest expense was $727 million in 2025, up from $674 million in 2024, consuming roughly a third of operating income. The debt structure includes a mix of term loans, revolving credit facilities, and senior unsecured notes with maturities spread from 2025 through 2032. The company amended its credit agreement in December 2025 to reduce interest rates on portions of its floating-rate debt.
IQVIA is not in distress. It generates more than enough cash to service the debt, and its credit facilities include substantial undrawn capacity. But the leverage constrains strategic flexibility. The company spent $1.8 billion on acquisitions in 2025 and $1.2 billion on share repurchases, both funded partly by incremental borrowing. Every capital allocation decision happens in the context of a $15.8 billion debt balance that needs to be refinanced over time.
Cash Flow
| Item | 2025 | 2024 |
|---|---|---|
| Operating cash flow | $2.65B | $2.79B |
| Capital expenditures | $594M | $543M |
| Free cash flow | $2.06B | $2.25B |
| Acquisitions | $1.80B | $405M |
| Share repurchases | $1.20B | $2.06B |
Free cash flow conversion is strong. Management reported that free cash flow represented 99% of adjusted net income in 2025. The business does not require heavy capital expenditure relative to its revenue base, which is typical of services and data companies. The $594 million in capex includes both physical infrastructure and capitalized software development.
Capital allocation has favored returning cash to shareholders and doing acquisitions over paying down debt. The company repurchased 7.4 million shares in 2025 at an average price around $162. Over the past several years, IQVIA has been a consistent and aggressive buyer of its own stock, reducing the diluted share count from roughly 195 million in 2021 to 175 million in 2025.
Management and Governance
Ari Bousbib has run IQVIA since the merger and served as CEO of IMS Health since 2010. His total compensation in 2025 was $24.4 million, including a base salary of $1.55 million, a $4.0 million cash bonus, and $18.4 million in equity awards. The board approved a new five-year employment agreement in 2024 with a $1.6 million base salary and annual equity grants targeting $15 million.
Bousbib’s track record over the past nine years has been one of steady operational execution. Revenue has grown from roughly $10 billion at the time of the merger to $16.3 billion, margins have expanded, and the integration of two very different corporate cultures (data analytics and clinical research) has not produced visible operational disruptions. The share count has declined meaningfully through buybacks.
The CFO transition is worth noting. Ronald Bruehlman, who served as CFO through the entire post-merger period, retired from the role effective February 28, 2026. His successor is Michael Fedock, a 25-year healthcare industry veteran who joined IQVIA in 2016 and most recently ran financial planning and analysis. Fedock previously served as CFO of the R&D Solutions segment and as CFO of the Quest Diagnostics laboratory joint venture. The transition was planned well in advance, with Bruehlman moving to a Senior Advisor role to ensure continuity.
The board added William G. Kaelin Jr., M.D. in November 2025. Kaelin won the 2019 Nobel Prize in Physiology or Medicine for research on how cells sense and adapt to oxygen availability. The appointment was a direct response to shareholder feedback requesting more scientific expertise on the board. The proxy statement describes Kaelin’s addition as strengthening oversight of IQVIA’s R&D strategy and its growing investment in AI-driven drug development tools.
Insider ownership is modest. Bousbib and other executive officers hold meaningful equity positions through stock awards, but the company’s ownership structure is predominantly institutional. As of February 2026, there were only 11 registered stockholders of record, reflecting the typical pattern of shares held through brokerage accounts.
The AI Bet
IQVIA is investing heavily in artificial intelligence, and the 10-K makes clear that management views AI as both the company’s largest opportunity and its most significant competitive threat.
On the offensive side, the company filed over 90 AI patent applications in 2025 and deployed more than 150 specialized AI agents across clinical and commercial workflows. Management has branded this effort “Healthcare-grade AI,” emphasizing that IQVIA’s models are trained on its proprietary data and built to meet the regulatory and validation requirements specific to pharmaceutical and healthcare applications. Strategic partnerships with AWS, NVIDIA, Microsoft, Oracle, and Palantir provide cloud infrastructure and compute capacity.
Specific AI applications include automated clinical trial site selection, AI-driven patient matching for trial enrollment, predictive analytics for drug launch planning, and natural language processing for adverse event detection. The company launched a “Global Market Insights Agent” and a “Clinical Trial Financial Suite” powered by its AI infrastructure.
On the defensive side, the risk factors section is unusually candid. The company acknowledges that AI could reduce the value of its services if pharmaceutical companies develop internal capabilities to analyze large healthcare datasets, design clinical trials, or generate real-world evidence without IQVIA’s help. The risk is not hypothetical. Large language models are already capable of processing medical literature and clinical data at scale, and the cost of AI inference continues to fall. If a top-20 pharmaceutical company decides it can build an internal analytics platform using open-source AI tools and its own data, IQVIA loses a high-margin client.
The counter-argument is that IQVIA’s data is the bottleneck, not the analytics layer. A pharmaceutical company can build sophisticated AI models, but those models need data to train on. IQVIA’s 1.2 billion patient records, 68 petabytes of longitudinal data, and 150,000 data supplier relationships are not available on the open market. The company is betting that proprietary data plus specialized AI is more valuable than generic AI plus whatever data a client can assemble independently.
Whether that bet pays off will likely be the defining strategic question for IQVIA over the next five years.
Valuation
IQVIA generates real cash, but the capital structure means any valuation exercise has to start at the enterprise level and work down through $13.8 billion in net debt before arriving at equity value. The gap between GAAP earnings and adjusted earnings also forces a choice about which profit metric best represents the company’s earning power.
Which Earnings to Use
GAAP net income was $1.36 billion in 2025. Adjusted net income was $2.07 billion. The difference is driven primarily by $636 million in amortization of acquisition-related intangibles, $203 million in stock-based compensation, and $167 million in restructuring costs.
The amortization is real in the sense that IQVIA paid for those intangible assets in the merger, and the balance sheet carries $12.4 billion in goodwill and $4.5 billion in other intangibles as a result. But it is non-cash, and the underlying data assets and customer relationships are not depleting the way a patent portfolio might. Stock-based compensation is a real economic cost to shareholders through dilution, though the company has more than offset it with buybacks. Restructuring charges have been recurring for years, which raises the question of whether they are truly non-recurring.
For valuation purposes, free cash flow is the cleanest measure. IQVIA generated $2.06 billion in free cash flow in 2025 on 175 million diluted shares, or $11.77 per share. This is after all cash taxes, interest payments, and capital expenditures.
Method 1: EV/EBITDA
IQVIA’s adjusted EBITDA was $3.8 billion in 2025. Healthcare services and data companies with comparable growth profiles (mid-to-high single digits), recurring revenue characteristics, and strong cash conversion typically trade in the 10-14x EBITDA range, depending on competitive positioning and growth visibility.
| Scenario | Multiple | Enterprise Value | Less Net Debt | Equity Value | Per Share |
|---|---|---|---|---|---|
| Bear | 10x | $38.0B | $13.8B | $24.2B | $138 |
| Base | 12x | $45.6B | $13.8B | $31.8B | $182 |
| Bull | 14x | $53.2B | $13.8B | $39.4B | $225 |
The bear case reflects a scenario where AI disruption compresses margins, biotech funding dries up, or the debt load becomes a drag during a refinancing cycle. The base case assumes continued execution at current growth rates with stable margins. The bull case assumes the AI investments pay off, the Salesforce partnership generates meaningful incremental revenue, and the company successfully deleverages.
Method 2: Free Cash Flow Yield
Working directly from free cash flow avoids the adjustments debate entirely. IQVIA’s $2.06 billion in free cash flow, growing at management’s targeted 6-9% annually, can be valued at different required yield levels.
| Scenario | Required FCF Yield | Implied Equity Value | Per Share |
|---|---|---|---|
| Bear | 7.0% | $29.4B | $168 |
| Base | 5.5% | $37.5B | $214 |
| Bull | 4.5% | $45.8B | $262 |
A 7% FCF yield reflects skepticism about growth durability and concern about the debt load. A 5.5% yield is consistent with a business that compounds free cash flow at mid-single digits with high conversion. A 4.5% yield requires confidence in the data moat’s durability and continued margin expansion.
Method 3: Owner Earnings
A more conservative approach starts with GAAP net income and adds back only the clearly non-cash acquisition amortization, then subtracts an estimate of maintenance capital expenditure.
- GAAP net income: $1.36B
- Add back: acquisition-related amortization: $636M
- Less: estimated maintenance capex (roughly $400M of the $594M total): ($400M)
- Owner earnings: $1.60B, or $9.14 per share
| Scenario | Multiple | Equity Value | Per Share |
|---|---|---|---|
| Bear | 15x | $24.0B | $137 |
| Base | 18x | $28.8B | $165 |
| Bull | 22x | $35.2B | $201 |
This method produces lower values because it treats stock-based compensation as a real cost (it stays in the GAAP net income figure) and uses a more conservative starting point. The 15-22x range reflects the company’s growth profile and competitive position, with the low end discounting for leverage risk and the high end crediting the data moat.
Synthesis
| Scenario | EV/EBITDA | FCF Yield | Owner Earnings | Average |
|---|---|---|---|---|
| Bear | $138 | $168 | $137 | $148 |
| Base | $182 | $214 | $165 | $187 |
| Bull | $225 | $262 | $201 | $229 |
The three methods converge on a base case equity value in the range of $165 to $214 per share, with an average around $187. The wide range reflects genuine uncertainty about how to value the data moat, how much credit to give the adjusted earnings, and how to weigh the leverage risk.
The most important variable is not the multiple. It is whether IQVIA’s proprietary data retains its pricing power as AI tools become more accessible. If the moat holds, the base-to-bull range is reasonable. If pharmaceutical companies find that open-source AI plus their own internal data produces 80% of the insight at 20% of the cost, the bear case understates the downside.
If you found this helpful, consider supporting my work. This blog has no paywalled content and reader support is how it stays that way. You can also subscribe to my mailing list to get new deep dives in your inbox.
What to Watch
| Catalyst | Why It Matters | Timeline |
|---|---|---|
| Q1 2026 earnings under new segment structure | First results reported as Commercial Solutions and R&D Solutions; will reveal margin profiles of the reorganized business | Late April 2026 |
| CFO transition execution | Michael Fedock took over as CFO on February 28, 2026; first earnings call as CFO will signal continuity or strategic shifts | Q1 2026 earnings call |
| Salesforce/IQVIA CRM adoption metrics | Any disclosure of customer wins against Veeva would indicate partnership traction; absence of disclosure suggests limited momentum | Ongoing through 2029 |
| Vault CRM migration progress at Veeva | Every customer Veeva successfully migrates to Vault is one fewer opportunity for the Salesforce/IQVIA partnership to capture | Veeva earnings through December 2029 |
| Biotech funding environment | Smaller biotech clients fund clinical trials with venture capital; a sustained VC downturn directly impacts R&D Solutions backlog conversion | Ongoing |
| Debt refinancing schedule | Portions of the $15.8 billion debt stack mature through 2032; terms on refinancings will affect cash available for shareholders | 2026-2028 maturities |
| AI product revenue contribution | Whether IQVIA’s 150+ AI agents and Healthcare-grade AI platform generate measurable incremental revenue or remain cost optimization tools | 2026-2027 |
| Net leverage ratio trend | Management has not stated a specific deleveraging target; movement below 3.5x would signal balance sheet discipline, movement above 4.0x would raise concerns | Quarterly |
Sources:
- 10-K filed February 17, 2026
- DEF 14A filed February 27, 2026
- 8-K filed September 2, 2025 (CFO succession)
- 8-K filed November 5, 2025 (Kaelin board appointment)
- 8-K filed December 9, 2025 (credit agreement amendment)
- Veeva Systems 10-K filed March 20, 2026
Research and analysis conducted with AI assistance using SEC EDGAR filings as primary sources.